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IgGAbstract Background: COPD may be associated with other systemic diseases including cardiovas-
cular diseases, diabetes, osteoporosis and peptic ulceration and Helicobacter pylori infection seems
to be the main cause of PUD.
Aims: The aim of this work is to study the association of H. pylori infection in chronic obstruc-
tive pulmonary disease (COPD).
Subject and methods: This study was performed on 80 subjects. They were classified into two
groups: Group I: 65 COPD patients. Group II: 20 healthy control subjects. COPD was diagnosed
according to the Global Initiative for chronic obstructive pulmonary disease admitted at chest
department of Benha University Hospital.
Results: It shows that seropositivity of anti-H. pylori IgG and anti-CagA IgG was higher in
COPD patients than in controls with a highly statistically significant difference (p= 0.009 and
0.047 respectively). Also the IgG level ofH. pylori positive cases and CagA positive cases was higher
in the COPD group than in the control group with a highly statistically significant difference
(p= 0.027 and 0.0001 respectively).
Conclusion: The present study suggests that patients with COPD have an increased seropreva-
lence of Hp infection.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Chronic obstructive pulmonary disease (COPD) is a common
preventable and treatable disease. It is characterized bypersistent airflow limitation that is usually progressive. It is
associated with abnormal chronic inflammatory response to
noxious particles or gases. Exacerbations and co-morbidities
contribute to the overall severity in individual patients [1].
Helicobacter pylori is a slow growing, microaerophilic,
gram-negative spiral shaped bacterium. It colonizes gastric
mucosa and elicits both inflammatory and lifelong immune
responses with release of various bacterial and cytotoxic
Table 1 Demographic data in COPD patients and controls.
Variables Group (I) (COPD
patients) n= 65
Group (II)
(Controls)
n= 20
P
value
Age (years) 62.2 ± 9.3 60.6 ± 6.4 0.22
Gender Male 63 (96.9%) 18 (90%) 0.31
Female 2 (3.1%) 2 (10%)
Smoking 50 (76.9%) 5 (25%) 0.0001*
* Means significant.
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also been reported in various extragastrointestinal disorders
including skin, vascular, and autoimmune disorders, as well
as in some respiratory diseases such as bronchial asthma,
bronchiectasis, chronic bronchitis, and lung cancer [3].
COPD had been associated with gastroduodenal ulcer,
many years before the identification of H. pylori infection as
a cause of peptic ulcer disease [3]. Despite the fact that the role
of H. pylori in pathogenesis of COPD remains controversial
the activation of inflammatory mediators byH. pylori infection
and during the course of COPD may explain the potential
pathogenetic role of H. pylori [4]. Data in the literature on
the relationship between H. pylori infection and chronic
obstructive pulmonary disease (COPD) are poor [3].
Subjects and methods
The present study is a cohort prospective study. It was con-
ducted in the period extending from January 2014 to January
2015 after obtaining informed patients’ consent.
Subjects
This study was performed on 85 subjects. They were classified
into two groups:
▪ Group I included 65 COPD patients.
▪ Group II included 20 healthy control subjects.
Inclusion criteria: COPD was diagnosed according to the
Global Initiative for chronic obstructive pulmonary disease
(GOLD) admitted at chest department of Benha University
Hospital. Severity of COPD will be classified by spirometric
data according to guidelines of Global Initiative for chronic
obstructive lung disease [1]. The studied groups were com-
plaining of dyspeptic symptoms (as abdominal pain related
to meals, fullness, early satiety and nausea) or history of peptic
ulcer.
Exclusion criteria: Patients with exacerbation of COPD in
the preceding month, as in those cases pulmonary function
does not represent baseline levels, prior H. pylori eradication
therapy, history of taking of acid suppressive drugs or antibi-
otics in the preceding 6 months, and history of vagotomy or
operation on the upper gastrointestinal tract.
All patients were submitted to:
(1) Full history and thorough clinical examination (stress
on dyspeptic symptoms and history of peptic ulcer).
(2) Radiological examination: plain postero-anterior and
lateral chest X-ray.
(3) Ventilatory function test (spirometry) before and after
bronchodilatation.
(4) H. pylori antibody level positive detection was measured
by ELISA using specific kits for anti-H. pylori IgG (Cat-
alog No. E-HL G-K08) and anti-CagA H. pylori IgG
[DIA. PRO (Diagnostic Bioprobes) SrlVia G. Carducci
no 27 20099 Sesto San Giovanni (Milano)- Italy]. Puri-
fied antigens are coated to a microwell plate. Antibodies
in the patient samples bind to the antigens and were
determined during the second incubation step using
enzyme-labeled antihuman antibodies (the conjugate).All unbound materials are removed by washing. The
bound enzyme converts the colorless substrate (H2O2/
TMB) to a blue end product.
Statistical analysis
Data obtained from the present study were computed using
SPSS versions 17 under the platform of Microsoft Windows
XP, Professional Edition. Continuous data were expressed in
the form of mean ± SD while categorical data were expressed
in the form of count and percent. Comparison of continuous
data was performed utilizing student t test, while categorical
data were done using Chi-square test. P value less than 0.05
was considered statistically significant.
Results
Table 1 shows a highly significant difference between them as
regards smoking (p= 0.0001).
Table 2 shows that seropositivity of anti-H. pylori IgG and
anti-CagA IgG were higher in COPD patients than controls
with a highly statistically significant difference (p= 0.009
and 0.047 respectively). Also IgG level of H. pylori positive
cases and CagA positive cases were higher in the COPD group
than in the control group with a highly statistically significant
difference (p= 0.027 and 0.0001 respectively).
Table 3 shows no statistically significant differences
between COPD patients with anti-H. pylori +ve and ve
IgG regarding pulmonary functions.
Table 4 shows there is significantly lower FEV1 in anti-CagA
+ve patients when compared with anti-CagA ve patients with
a statistically significant difference and (p= 0.011).
Table 5 shows the majority of anti-CagA +ve patients had a
significantly higher frequency of severe disease 26 (72.2%) with a
highly statistically significant difference between 2 groups
(p= 0.02).
Table 6 shows a statistically significant correlation between
anti-CagA seropositivity and both disease severity and FEV1.
Discussion
The pulmonary component of chronic obstructive pulmonary
disease (COPD) is characterized by airflow limitation that is
not fully reversible [5]. H. pylori is a major causative agent
of peptic ulcer disease and a risk-factor for gastric cancer [6].
It is believed that the release of proinflammatory cytokines
stimulated by H. pylori may play a role in chronic inflamma-
tion of bronchi. Cytotoxin-associated gene-A (CagA) is the
most important virulence factor for H. pylori that affects
Table 2 Serological parameters in the studied subjects.
Variables Group (I) (COPD patients) n= 65 Group (II) (Controls) n= 20 P
Anti-H. pylori IgG seropositivity (%) 41 (63.1%) 6 (30.0%) 0.009*
Anti-H. pylori IgG level (U/ml) 29.3 ± 21.8 17.1 ± 12.3 0.027*
Anti-CagA IgG seropositivity (%) 36 (55.4%) 6 (30.0%) 0.047*
Anti-CagA IgG level (U/ml) 25.3 ± 18.3 12.4 ± 9.8 0.0001*
* Means significant.
Table 3 Comparison between anti-H. pylori +ve and ve
IgG COPD patients regarding pulmonary functions.
Variables Anti-H. pylori +ve
n= 41
Anti-H. pylori ve
n= 24
P
FEV1 48.1 ± 12.4 51.5 ± 16.3 0.35
FVC 51.9 ± 15.2 54.2 ± 17.5 0.57
FEV1/FVC 58.9 ± 12.9 60.5 ± 13.9 0.64
MVV 33.6 ± 13.2 35.7 ± 18.1 0.59
Table 4 Comparison between anti-CagA IgG +ve and ve
patients regarding pulmonary function tests.
Anti-CagA+ ve
n= 36
Anti-CagA –ve
n= 29
P
FEV1 45.2 ± 13.4 53.5 ± 14.5 0.011*
FVC 52.2 ± 15.0 53.2 ± 17.1 0.79
FEV1/FVC 60.5 ± 13.3 58.6 ± 13.3 0.56
MVV 35.1 ± 14.5 33.7 ± 15.8 0.7
* Means significant.
Table 5 Comparison between anti-CagA IgG +ve and ve
patients regarding disease severity.
Degree of disease
severity
Anti-CagA +ve
n= 36
Anti-CagA ve
n= 29
P
Mild 1 (2.8%) 4 (13.8%) 0.02*
Moderate 8 (22.2%) 14 (48.3%)
Severe 26 (72.2%) 11 (37.9%)
Very severe 1 (2.8%) (0%)
* Means significant.
Table 6 Correlation between anti-CagA seropositivity and all
studied parameters.
Anti-CagA seropositivity
R P
Age 0.1 0.41
Disease severity 0.43 0.0001*
FEV1 0.34 0.005*
FVC 0.06 0.6
FEV1/FVC 0.028 0.28
MVV 0.4 0.75
* Means significant.
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may induce more inflammatory response in COPD and other
inflammatory disorders [7].
The present study aimed to study the association ofH. pylori
infection in chronic obstructive pulmonary disease (COPD) and
its relation to severity of the disease. As shown in Table 1, there
was an immense dominance of males in the COPD patients
(96.9%) with no statistically significant differences between
patients and controls regarding age and gender distribution.
Also there is a highly significant difference between patients
and control as regards smoking (p= 0.0001). Cigarette smok-
ing is by far the most important risk factor for development of
COPD. Earlier studies reported that 15% up to 20% of smok-
ers develop COPD, although this number may reach 50% in
elderly smokers [8].As shown in Table 2 we found that the seropositivity of anti-
H. pylori IgG and anti-CagA IgG was higher in COPD patients
than in controls with a highly statistically significant difference
(p= 0.009 and 0.047 respectively). Also IgG level of H. pylori
positive cases and CagA positive cases were higher in the COPD
group than in the control group with a highly statistically signif-
icant difference (p= 0.027 and 0.0001 respectively).
The higher prevalence of H pylori infection in COPD
patients in comparison with controls was also noted by the
study of Pro´nai et al. [9], who found that the prevalence of
H. pylori compared to the age-matched controls is significantly
higher in patients with chronic obstructive pulmonary disease.
Also this coordinates with the study of Gencer et al. [10],
they aimed to investigate seroprevalence in H. pylori patients
with COPD and to determine whether there is an association
between H. pylori infection and COPD. Forty-nine voluntary
patients with COPD and 50 healthy control subjects of similar
age and sex were included in the study. Serum levels of H.
pylori specific IgG and H. pylori IgG seropositivity were signif-
icantly higher in the patients with COPD than in the control
subjects.
In addition to the study of Roussos et al. [3], in which they
searched for the seroprevalence of H. pylori and in particular
of CagA-positive virulent strains in patients with chronic
obstructive pulmonary disease (COPD), 126 COPD patients
(88 males and 38 females, aged 61.3 ± 8.1 years) and 126,
age and sex-matched, control subjects were investigated. The
prevalence of H. pylori infection in patients and controls was
77.8% and 54.7%, respectively (P< 0.001) and that of
CagA-positive H. pylori infection was 53.9% and 29.3%,
respectively (P< 0.001).
But in Hashemi et al’. [4] study, when they investigated the
association between H. pylori and chronic obstructive pul-
monary disease (COPD). In this case-control study, 90 patients
with COPD and 90 age- and sex- matched control subjects
were included. Serum samples were tested for anti-H. pylori
IgG and anti-CagA IgG by ELISA. There was no significant
association between H. pylori IgG seropositivity and COPD
570 S.A. Eisa et al.while Serum levels of anti-CagA IgG were significantly higher
in patients with COPD than in the control subjects
(P< 0.001).
Several studies found that H. pylori infection was associ-
ated with extragastroduodenal pathologies characterized by
activation of inflammatory mediators or induction of autoim-
munity. This arose the interest of researchers to search for H.
pylori to recognize its role in several diseases outside GIT.
They found that H. pylori seroprevalence was high in certain
diseases as IHD, vascular, rosacea, skin and even in some chest
diseases as active bronchiectasis. In 1998 a pilot study in a
small number of Italian patients showed that H. pylori per
se, might be related to a high risk of developing chronic bron-
chitis [5]. Also the prevalence of COPD in peptic ulcer patients
increases 2–3-folds compared with findings in ulcer free con-
trols as proved by epidemiological study done between 1968
and 1986 [11,12]. Moreover, eradication of H. pylori leads to
normalization of serum cytokines levels [13], these cytokines
are also thought to be involved in the pathogenesis of COPD
[14]. Therefore, H. pylori infection in general and CagA posi-
tive strains in particular may play a proinflammatory role
and co-trigger COPD with other more specific environmental,
genetic and unknown factors.
Another potential mechanism could be the spilling or
inhalation of H. pylori or its toxins into the respiratory tract
which also might lead to chronic airway inflammation such
as COPD [12]. However, as far as we know, neither identifica-
tion of H. pylori species in human bronchial tissue, nor isola-
tion of H. pylori from bronchoalveolar lavage fluid has been
achieved yet [15]. Certain studies found that H. pylori was
not found in bronchial biopsies of patients with various respi-
ratory diseases, which suggested that no direct evidence sup-
porting the theory that H. pylori may cause pulmonary disease
and no relation with GERD was detected [16,17].
Also this coordinate with the study of Shams-Hosseini et al.
[18] they perform study on 32patients with any pulmonary dis-
ease undergoing bronchoscopy and biopsy samples were
obtained from them. Three bronchial mucosa biopsy
specimens were obtained by fenestrated biopsy forceps for
pathologic assessment from carina, using a fiberoptic broncho-
scope. One of these samples was used to determine urease
activity. They used hematoxylin-eosin staining for histopatho-
logical evaluation of the presence of H. pylori in the second
mucosa sample and the third specimen was used for
histopathological diagnosis, they found that no correlation
was detected between histopathological evaluation and urease
test for H. pylori in lung specimens. However, a possible indi-
rect role could not be excluded.
As regards our study in comparison between patients with
anti-CagA +ve and anti-CagA ve regarding pulmonary
functions it revealed significantly lower FEV1 in anti-CagA
+ve patients when compared with anti-CagA ve patients.
Also, there was a statistically significant inverse correlation
between FEV1 and anti-CagA titer (p= 0.005), while no sta-
tistically significant differences between COPD patients with
anti-H. pylori +ve and ve IgG regarding pulmonary func-
tions as shown in Tables 3 and 4 it revealed that disagreement
with Gencer et al. [10] as they found that FEV 1, which is one
of the respiratory parameters indicating airway damage and
the severity of inflammation, was lower in Hp-seropositive
COPD patients, than in seronegative ones (p= 0.014) suggest-
ing that Hp is associated with airway inflammation.This incoordinates with the study of Roussos et al. [2], in
which the spirometric values showed that no statistically signif-
icant difference, as regards the values, was detected betweenH.
pylori infected COPD patients and uninfected ones as the
spirometric values did not differ significantly between COPD
patients infected with CagA-positive strains of COPD patients
in relation with H. pylori infection.
Moreover, as shown in Tables 5 and 6 we found that the
majority of anti-CagA +ve patients had a significantly higher
frequency of severe disease 26 (72.2%) with a highly statisti-
cally significant difference between 2 groups (p= 0.02),
although there were no statistically significant differences
between 2 groups regarding anti-H. pylori IgG. There is a sta-
tistically significant correlation between anti-CagA and both
disease severity and FEV1.
This result coordinates with another study which showed
that the prevalence of positive H. pylori serology in a group of
COPD patients stratified according to disease severity and in a
control group matched for age, socioeconomic class and pack
year smoking history. The prevalence of positiveH. pylori serol-
ogy was significantly higher in patients with COPD (54.7%)
compared with the control group (23.5%; p= 0.026) [19].
While in the study of Hashemi et al. [4] they found that no
significant association was found between the severity of
COPD and the frequency of anti-H. pylori IgG and anti-
CagA IgG seropositivity. As explanation for positive results
they found that CagA positive are those strains that induce
increased local and systemic, humoral and cellular inflamma-
tory response [20]. With regard to the potential etio-
pathogenic role of H. pylori infection in COPD, the chronic
activation of inflammatory mediators induced by H. pylori
infection might lead to the development of COPD, the
increased prevalence of CagA positive strains further supports
this hypothesis, it is well known that these virulent strains
stimulate the release of a variety of proinflammatory cytoki-
nes, including interleukin-1 (IL-1), IL-8 and tumor necrosis
factor-alpha [21,22].
Fedorova et al. [23], found a significant increase in the inci-
dence of gastritis in patients with COPD and emphasized the
effect of H. pylori. They also detected a correlation between
the duration of COPD, hypoxia and the degree of bronchial
obstruction and the severity of gastritis. H. pylori seropositiv-
ity may be an important factor that should be kept in mind
while approaching and treating dyspeptic symptoms in
patients with COPD. Conclusively, the present study found a
significant link between COPD and H. pylori infection and a
significant association between disease severity and anti-
CagA +ve cases. Further studies assessing the effect of Hp
infection on the pathogenesis of COPD and on the effect of
Hp eradication on COPD are required.Conflict of interest
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